Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2020 Jan 15;20(5):e221–e238. doi: 10.1016/j.clml.2020.01.001

Table 2.

MRD status by IMWG response assessment.

MRD negative (n=72) MRD positive (n=61) p-value
sCR + CR (n=59), n(%) 54 (91.5) 5 (8.5) < 0.001
VGPR* (n=44), n(%) 13 (29.5) 31 (70.5)
PR* (n=30), n(%) 5 (17) 25 (83)
*

Patients with either VGPR or PR are considered to be flow bone marrow aspirate negative at MRD level of detection rather than MRD negative.